GABA-glutamate Interactions and Psychosis
Trial Purpose and Description
This study investigates the interactions between NMDA (N-Methyl-D-aspartic acid) antagonism and GABA (gamma-aminobutyric acid) system as it relates to cognitive function assessed by ERPs (event-related potentials) in healthy volunteers.
- 21 Years - 45 Years
- Ages of 21-45 years from all ethnic backgrounds.
- Male or female.
- Written informed consent.
- DSM-IV diagnosis for a psychotic, depressive or anxiety disorder.
- A history of significant medical/neurological disease such as cardiac, thyroid,
renal, hepatic abnormality, seizure disorder. Unstable medical condition based on
EKG, vital signs, physical examination and laboratory work-up (CBC with differential,
SMA-7, LFTs, TFTs, UA, Utox).
- History of abnormal EEG.
- History of severe allergies or multiple adverse drug reactions.
- Any medication that could interfere with either the safety of the study and/or the
- Any other conditions which in the opinion of the investigator would preclude
participation in the study.
- History of major psychiatric disorder in first degree relatives.
- Current substance abuse/dependency determined by urine toxicology.
- Treatment with medications with CNS effects.
- Treatment with benzodiazepines within one week prior to testing.
- Current treatment with medications with psychotropic effects.
- Education < 10th grade.
- IQ < 70, MR.
- Non-English speaking.
- National Alliance for Research on Schizophrenia and Depression
- Yale University
- January 2007
- Last Updated:
- May 17, 2012
- Study HIC#:
Clinicaltrials.gov ID: NCT00611572